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Background: Eleven new human polyomaviruses (HPyVs) have been identified in the last decade. Serological
studies show that these novel HPyVs sub-clinically infect humans at an early age. The routes of infection, entry
pathways, and cell tropism of new HPyVs remain unknown. VP1 proteins of polyomaviruses can assembly into
virus-like particles (VLPs). As cell culturing systems for HPyV are currently not available, VP1-derived VLPs may be
useful tools in basic research and biotechnological applications.
Results: Recombinant VP1-derived VLPs from 11 newly identified HPyVs were efficiently expressed in yeast. VP1
proteins derived from Merkel cell polyomavirus (MCPyV), trichodysplasia spinulosa-associated polyomavirus (TSPyV),
and New Jersey polyomavirus (NJPyV) self-assembled into homogeneous similarly-sized VLPs. Karolinska Institutet
polyomavirus (KIPyV), HPyV7, HPyV9, HPyV10, and St. Louis polyomavirus (STLPyV) VP1 proteins formed VLPs that
varied in size with diameters ranging from 20 to 60 nm. Smaller-sized VLPs (25–35 nm in diameter) predominated
in preparations from Washington University polyomavirus (WUPyV) and HPyV6. Attempts to express recombinant
HPyV12 VP1-derived VLPs in yeast indicate that translation of VP1 might start at the second of two potential
translation initiation sites in the VP1-encoding open reading frame (ORF). This translation resulted in a 364-amino
acid-long VP1 protein, which efficiently self-assembled into typical PyV VLPs. MCPyV-, KIPyV-, TSPyV-, HPyV9-,
HPyV10-, and HPyV12-derived VLPs showed hemagglutination (HA) assay activity in guinea pig erythrocytes,
whereas WUPyV-, HPyV6-, HPyV7-, STLPyV- and NJPyV-derived VP1 VLPs did not.
Conclusions: The yeast expression system was successfully utilized for high-throughput production of recombinant
VP1-derived VLPs from 11 newly identified HPyVs. HPyV12 VP1-derived VLPs were generated from the second of
two potential translation initiation sites in the VP1-encoding ORF. Recombinant VLPs produced in yeast originated
from different HPyVs demonstrated distinct HA activities and may be useful in virus diagnostics, capsid structure
studies, or investigation of entry pathways and cell tropism of HPyVs until cell culture systems for new HPyVs are
developed.
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Polyomaviruses (PyVs) are small, non-enveloped viruses
with a circular, double-stranded genome comprised of
approximately 5000 base pairs surrounded by an icosa-
hedral capsid [1]. PyVs have been found to infect both
mammalian (Orthopolyomavirus and Wukipolyomavirus)
and avian (Avipolyomavirus) species [2, 3]. Mammalian* Correspondence: agedv@ibt.lt
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were originally identified and named for their ability to
cause multiple types of tumors [4]. BK polyomavirus
(BKPyV) and JC polyomavirus (JCPyV) were the first two
human PyVs (HPyVs) isolated 40 years ago [5, 6]. As a re-
sult of improved molecular diagnostic techniques, com-
bined with strategies in sample preparation to enrich viral
DNA content through reduction of host genomic DNA,
11 new HPyVs have been identified in the last decade. Of
these novel HPyVs, Karolinska Institutet polyomavirus
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first to be discovered [7–9]. Later, HPyV6, HPyV7, tricho-
dysplasia spinulosa-associated polyomavirus (TSPyV), and
HPyV9 were identified [10–12]. By 2014, three more
HPyVs (HPyV10, St. Louis polyomavirus (STLPyV), and
HPyV12) were discovered [13–15]. Two other PyVs de-
tected in human stool samples, Malawi polyomavirus
(MWPyV) and Mexico polyomavirus (MXPyV), may rep-
resent strain variants of HPyV10 because their genomes
are 95–99 % identical [16, 17]. The latest virus, New Jersey
polyomavirus (NJPyV), was discovered in endothelial cells,
sites of myositis, and sites of cutaneous necrosis in a pan-
creatic transplant recipient [18].
Discoveries of new HPyVs have revived interest in this
expanding family of human pathogens. There are several
reasons why HPyVs may be important in human path-
ology. First, according to serological studies, HPyVs sub-
clinically infect humans at an early age, with rates
ranging from 35 to 90 % [19, 20]. Secondly, while HPyV
infection is generally asymptomatic, it can cause serious
illness in immunocompromised individuals [19]. Accord-
ingly, the involvement of some HPyVs in the pathology
of various diseases has been reported. Infection by and
replication of BKPyV in kidney epithelial cells can lead
to PyV-associated nephropathy [21, 22]. Progressive
multifocal leukoencephalopathy is caused by uncon-
trolled JCPyV replication in oligodendrocytes of the
brain in immunosuppressed patients, including patients
with advanced acquired immune deficiency syndrome
(AIDS) [22, 23]. Trichodysplasia spinulosa, a rare skin
dysplasia, occurs in immunocompromised individuals as
a result of TSPyV replication in the inner root sheath
cells of hair follicles [11]. HPyV7 has also been associ-
ated with novel pathogenicity: lower back rash in im-
munosuppressed patients [24]. Thirdly, several PyVs may
be associated with human cancer. MCPyV has gained
the most attention due to its link with a rare and aggres-
sive malignant human skin cancer, Merkel cell carcin-
oma, in the elderly and chronically immunosuppressed
individuals [19]. It has been shown that hamster polyoma-
virus (HaPyV) is responsible for the high incidence of
lymphomas in a colony of genetic audiogenic seizure ham-
sters (GASH:Sal) [25]. Moreover, proteins encoded by
some PyVs have transforming ability in cell culture and
tumorigenic activity in animals [26]. The connection with
disease of other new HPyVs has yet to be determined.
The late gene region of mammalian PyVs encode three
structural proteins, VP1, VP2, and VP3, which together
make up the viral capsid; the capsid of avian PyVs may
additionally contain a unique VP4 protein [1, 27]. How-
ever, capsid-like structures can assemble of the major
capsid protein VP1 alone [28–30]. This unique property
of VP1 makes it an ideal protein for generating virus-
like particles (VLPs). VLPs resemble the native virionsthey are derived from in structure, immunogenicity, and
tropism, but they do not contain any viral genetic mater-
ial. VLPs are particularly valuable in various research ap-
plications because many PyVs are not easily cultured,
which may be related to the finding that PyVs infect only
a very limited number of species and cell types in nature
[1]. PyV VP1-derived VLPs play an important role in the
study of mechanisms underlying protein self-assembly, at-
tachment to host cell receptors, virus entry, immune re-
sponse, intracellular trafficking, and in the epidemiologic
study and diagnosis of PyV infection [1, 31]. VP1-derived
VLPs may also have potential use in vaccine development,
gene delivery in gene therapy, and other biomedical pur-
poses [31, 32]. Sequence alignment of VP1 from different
HPyVs shows high amino acid (aa) sequence identity be-
tween some HPyVs, resulting in occasional antibody
cross-reactivity [20]. Cross-reactivity has been observed
between HPyV6 and HPyV7 (69 % identity) or BKPyV and
JCPyV (78 % identity), but not between MCPyV, TSPyV,
HPyV9, or MWPyV [20, 33, 34].
We have previously demonstrated that Simian virus 40
(SV40)-, HaPyV-, BKPyV-, JCPyV-, and murine poly-
omavirus (MPyV)-derived VP1 VLPs can be efficiently
produced in the yeast (Saccharomyces cerevisiae) strain,
AH22-214, using the pFX7 expression plasmid [29, 30].
In this study, we showed that the applied yeast system
is also suitable for efficient expression and self-
assembly of VP1-derived VLPs from 11 novel HPyVs:
MCPyV, KIPyV, WUPyV, HPyV6, HPyV7, TSPyV, HPyV9,
MWPyV, STLPyV, HPyV12, and NJPyV. Yeast-expressed
recombinant VLPs were subjected to a hemagglutination
(HA) assay, which our findings suggest might be useful
in developing new HPyV diagnostic tools and in other
applications.
Results
Production of VP1-derived VLPs from MCPyV, KIPyV,
WUPyV, HPyV6, HPyV7, TSPyV, HPyV9, HPyV10, STLPyV
and NJPyV in yeast
For the production of KIPyV-, WUPyV-, HPyV6-,
HPyV7-, TSPyV-, HPyV9-, STLPyV-, and NJPyV-derived
VLPs in yeast, codons in the VP1-encoding open reading
frames (ORFs) from corresponding HPyV genomes were
optimized for expression in S. cerevisiae. A few devia-
tions from strict, high-frequency codon usage were
allowed for the insertion or removal of restriction endo-
nuclease recognition sites. HPyV10 VP1 gene was syn-
thesized according to the native virus gene sequence
without codon optimization. MCPyV VP1 gene was
amplified by polymerase-chain reaction (PCR) from the
MCPyV virus genome cloned from a healthy volunteer
skin swab. All 10 VP1-encoding genes were inserted in
the same site in the expression vector, pFX7 [29], under
the control of a galactose-inducible promoter.
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expressed in yeast transformed with pFX7 carrying
HPyV VP1-encoding ORFs, yeast lysates were analyzed
using sodium dodecyl sulfate-polyacrylamide gels (SDS-
PAGE) (Fig. 1a–j, line 2). The expression of all 10 con-
structs was detected in yeast lysates, and the expression
level of all VP1 proteins derived from different HPyVs
did not vary significantly. All 10 recombinant VP1 pro-
teins stayed in the soluble fraction after the centrifuga-
tion of yeast lysates (Fig. 1a–j, line 3). The solubility of
VP1 allowed for the efficient purification by sucrose and
CsCl gradient centrifugation (Fig. 1j, line 4). The yield of
purified VP1-derived VLPs ranged from 0.44 to 1.05 mgFig. 1 Analysis of the production of novel HPyV-derived VP1 proteins in ye
negative control sample of whole crude lysate of yeast transformed with p
VP1 (a), pFX7-WUPyV-VP1 (b), pFX7-MCPyV-VP1 (c), pFX7-HPyV6-VP1 (d), pF
HPyV10-VP1 (h), pFX7-STLPyV-VP1 (i), or pFX7-NJPyV-VP1 (j) plasmid; 3 - the
transformed with pFX7-KIPyV-VP1 (a), pFX7-WUPyV-VP1 (b), pFX7-MCPyV-VP
pFX7-HPyV9-VP1 (g), pFX7-HPyV10-VP1 (h), pFX7-STLPyV-VP1 (i), or pFX7-NJ
VP1 (c), HPyV6 VP1 (d), HPyV7 VP1 (e), TSPyV VP1 (f), HPyV9 VP1 (g), HPyV10 VP1
weight marker (Thermo Fisher Scientific Baltics) was loaded into lane Mper 1 g of wet yeast biomass (Table 1). The lower yields
of purified VP1 from HPyV6, HPyV7, HPyV10, and
NJPyV may have been the consequence of minor differ-
ences in expression level and solubility. On the other
hand, it is known that codon usage might influence the
efficiency of heterologous gene expression [35, 36].
Thus, the lower yield of HPyV10-derived VP1 could be a
result of the HPyV10 VP1-encoding gene sequence, as it
was not optimized for yeast expression. During purifica-
tion, KIPyV-, HPyV6-, and HPyV7-derived VP1 tended
to degrade. Therefore, additional bands in the SDS-
PAGE gel were observed (Fig. 1a, d, e, line 4). Highly-
soluble TSPyV- and HPyV9-derived VP1 were purifiedast using Coomassie blue-stained SDS-PAGE. In lanes: 1- in all gels,
FX7 plasmid; 2 - whole lysate of yeast transformed with pFX7-KIPyV-
X7-HPyV7-VP1 (e), pFX7-TSPyV-VP1 (f), pFX7-HPyV9-VP1 (g), pFX7-
soluble fraction recovered after centrifugation of whole lysate of yeast
1 (c), pFX7-HPyV6-VP1 (d), pFX7-HPyV7-VP1 (e), pFX7-TSPyV-VP1 (f),
PyV-VP1 (j) plasmid; 4 - purified KIPyV VP1 (a), WUPyV VP1 (b), MCPyV
(h), STLPyV VP1 (i), or NJPyV VP1 (j) protein. In all gels, pre-stained protein









Formation of VLPsa Yield of purified VP1 VLPs
from 1 g of wet yeast biomass, mgb
HA of guinea pig
erythrocytes
KIPyV Optimized 378 41.59 + 0.62 ± 0.05 +
WUPyV Optimized 369 39.87 + 0.61 ± 0.03 -
MCPyV Native 423 46.56 + 0,81 ± 0.04 +
HPyV6 Optimized 387 41.84 + 0.55 ± 0.04 -
HPyV7 Optimized 380 40.98 + 0.58 ± 0.03 -
TSPyV Optimized 375 41.52/ + 1.05 ± 0.04 +
HPyV9 Optimized 371 40,32 + 1.01 ± 0.03 +
HPyV10 Native 403 43.57 + 0.44 ± 0.04 +
STLPyV Optimized 401 43.54 + 0.62 ± 0.04 -
HPyV12 Optimized 380 42.16 +/− 0.05 ± 0.03 +
HPyV12 Native 364 40.39 + 0.42 ± 0.04 +
HPyV12 Optimized 364 40.39 + 1.02 ± 0.06 +
NJPyV Optimized 489 53.78 + 0.45 ± 0.03 -
aThe formation of VLPs was confirmed by negative stain electron microscopy
bThe values for the yield of VLPs are the average at least from three independent experiments
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(Table 1).
The ability of VP1 proteins to self-assemble into VLPs
was examined using negative staining electron micros-
copy. All 10 purified VP1 proteins formed VLPs (Fig. 2).
MCPyV-, TSPyV-, and NJPyV-derived VLPs were found
to be the most similar in size (Fig. 2c, f ) with diameters
of 45–50 nm (Fig. 2c, f, l). The particles formed by seven
other VP1 proteins were more variable in size with di-
ameters ranging from 25 to 55 nm. Although the major-
ity of VLPs in preparations from KIPyV, HPyV7, HPyV9,
HPyV10, and STLPyV were 40–50 nm in diameter
(Fig. 2a, e, g, h, i), fractions of smaller VLPs, 25–35 nm
in diameter, predominated in samples from WUPyV and
HPyV6 (Fig. 2b, d).
Production of HPyV12 VP1-derived VLPs in yeast
HPyV12 VP1 gene [GenBank:JX308829] encodes a 380-
aa-long protein. For production of HPyV12-derived VP1
VLPs in yeast, we used both the native virus gene se-
quence (HPyV12 VP1n380) and a version that was
codon-optimized for S. cerevisiae expression (HPyV12
VP1s380), synthesized by GenScript. Both VP1-encoding
genes were cloned into the expression vector, pFX7 [25],
and transformed into the yeast strain, AH22-214. Ex-
pression of HPyV12 VP1380, analyzed using SDS-PAGE,
was low using both versions of the gene (Fig. 3a). Our
attempts to purify HPyV12 VP1380 using sucrose and
CsCl gradient centrifugation did not achieve complete
purification (Fig. 3a, line 9). Impurities could not be re-
moved with additional centrifugation in sucrose or CsCl,
and they remained in the same fractions as the VP1 pro-
tein. The yield of partially-purified VP1380 was very low:only 0.05 mg per 1 g of wet yeast biomass. Examination
of HPyV12 VP1380 assembly into VLPs using negative
staining electron microscopy demonstrated that some
spherical structures could be found, which were approxi-
mately 40 nm in diameter and similar to the typical
capsomer-structured surface. However, the majority of
the recombinant VP1380 formed atypical, small (20 nm
in diameter) particles or aggregates (Fig. 2j).
In determining why we could not produce HPyV12-
derived VP1 VLPs in yeast, we noticed that the N-terminal
end of the HPyV12 VP1 protein sequence overhang in
the alignment with other VP1 protein sequences de-
rived from different PyVs (Fig. 4). On the other hand,
the N-terminal arm encoded within a sequence starting
from a second potential translation initiation site in the
VP1 gene appeared to be typical of PyV VP1 (Fig. 4).
Based on these observations, we decided to express
HPyV12 VP1 using a sequence that did not encode an
atypical, hydrophobic, 16-aa-long N-terminal peptide.
We used the native virus gene sequence (HPyV12
VP1n364) and one that was codon-optimized for S.cere-
visiae expression (HPyV12 VP1s364), starting at the sec-
ond translation initiation site. These were cloned in the
vector, pFX7, and transformed into the yeast strain,
AH22-214. Production of the 364-aa-long HPyV12
VP1364 protein was analyzed using SDS-PAGE. The ex-
pression level of VP1364 was greatly improved using
these sequences compared with using the longer ver-
sion of the gene (Fig. 3a, b). HPyV12 VP1364 was puri-
fied using sucrose and CsCl gradient centrifugation.
The yields of VP1364 were approximately 0.4 mg and
1 mg per 1 g of wet yeast biomass using the native gene
and the codon-optimized gene, respectively. The purity
Fig. 2 Detection of purified HPyV-derived VP1 VLPs using negative staining electron microscopy. Electron micrographs of: (a) - KIPyV VP1 VLPs,
(b) - WUPyV VP1 VLPs, (c) - MCPyV VP1 VLPs, (d) - HPyV6 VP1 VLPs, (e) - HPyV7 VP1 VLPs, (f) - TSPyV VP1 VLPs, (g) - HPyV9 VP1 VLPs, (h) - HPyV10
VP1 VLPs, (i) - STLPyV VP1 VLPs, (j) - HPyV12 VP1380 VLPs, (k) - HPyV12 VP1364 VLPs, and (l) - NJPyV VP1 VLPs produced in yeast. Bars, 100 nm
Norkiene et al. BMC Biotechnology  (2015) 15:68 Page 5 of 14
Fig. 3 Analysis of HPyV12-derived VP1 VLP production in yeast. a - Analysis of HPyV12 VP1380 VLP production in yeast using Coomassie
blue-stained SDS-PAGE. Production of HPyV12 VP1380 protein was analyzed in two yeast clones transformed with pFX7-HPyV12-VP1n380 plasmid
(lines 1–4) and two clones transformed with pFX7-HPyV12-VP1s380 plasmid (lines 5–8). In lanes: 1, 3 - whole lysate of both yeast clones
transformed with pFX7-HPyV12-VP1n380 plasmid; 2, 4 - the soluble fraction recovered after centrifugation of whole lysate of both yeast clones
transformed with pFX7-HPyV12-VP1n380 plasmid; 5, 7 - whole lysate of both yeast clones transformed with pFX7-HPyV12-VP1s380 plasmid; 6,
8 - the soluble fraction recovered after the centrifugation of whole lysate of both yeast clones transformed with pFX7-HPyV12-VP1s380 plasmid;
9 - purified HPyV12-VP1380 protein; M - pre-stained protein weight marker. b - Analysis of HPyV12 VP1364 production in yeast using Coomassie
blue-stained SDS-PAGE. Production of HPyV12 VP1364 protein was analyzed in two yeast clones transformed with pFX7-HPyV12-VP1n364 plasmid
(lines 1–4) and two clones transformed with pFX7-HPyV12-VP1s364 plasmid (lines 5–8). In lanes: 1, 3 - whole lysate of both yeast clones
transformed with pFX7-HPyV12-VP1n364 plasmid; 2, 4 - the soluble fraction recovered after centrifugation of whole lysate of both yeast clones
transformed with pFX7-HPyV12-VP1n364 plasmid; 5, 7 - whole lysate of both yeast clones transformed with pFX7-HPyV12-VP1s364 plasmid; 6,
8 - the soluble fraction recovered after the centrifugation of whole lysate of both yeast clones transformed with pFX7-HPyV12-VP1s364; 9 - purified
HPyV12-VP1364 protein; M - pre-stained protein weight marker (Thermo Fisher Scientific Baltics)
Fig. 4 Alignment of VP1 N-terminal aa sequences encoded in the
genomes of different PyVs. The aa residues encoded in the first of
two potential translation initiation sites are typed in blue; the
identical actual N-terminal aa residues are shown in red
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other HPyV VP1 proteins (Fig. 3b, line 9; Table 1).
Thus, using codon-optimized HPyV12 VP1364 clearly
increased expression and yield of the protein. Analysis
of the purified HPyV12 VP1364 lacking the 16-aa-long
N-terminal using negative staining electron microscopy
showed that this protein efficiently assembled into
VLPs that were 45–50 nm in diameter (Fig. 2k).
Collectively, these data suggest that the translation ini-
tiation site of VP1 was predicted incorrectly by the
HPyV12 genome sequence annotated in GenBank. The
second translation initiation site in the putative ORF en-
coding VP1 is more likely the true start site, resulting in
efficient translation of a 364-aa-long VP1 protein and it’s
self-assembly into VLPs.
Detection of purified HPyVs derived VP1 proteins by
Western blot
The sequence alignment of VP1 proteins derived from
different HPyVs showed 25–78 % degree of identity in
amino acid sequence [20], thus it is not likely that all
Norkiene et al. BMC Biotechnology  (2015) 15:68 Page 7 of 14purified VP1 proteins could be recognized by the same
antibody in one Western blot. Nevertheless, polyclonal
antibodies of some PyVs demonstrated cross-reactivity
in Western blots [20, 30]. Therefore, attempts were
made to detect the purified VP1 proteins derived from
HPyVs based on their cross-reactivities with anti-JCPyV,
anti-HaPyV, anti-MCPyV, and anti-WUPyV VP1 poly-
clonal antibodies. Polyclonal antibody raised against
JCPyV-VP1 protein cross-reacted with previously devel-
oped BKPyV VP1 protein (78 % identity) [30] as well as
with TSPyV (52 % identity), HPyV12 (54 % identity), and
HPyV13 (48 identity) VP1 proteins in Western blot
(Fig. 5b, lanes 3, 9, 13, 14). A high degree of cross-
reactivity of HPyV VP1 proteins was observed with
rabbit antiserum raised against HaPyV VP1 protein. This
antiserum failed to detect only KIPyV (31 % identity),
WUPyV (31 % identity), HPyV10 (47 % identity), and
STLPyV (43 % identity) VP1 proteins (Fig. 5c, lanes 4, 5,Fig. 5 Detection of purified HPyV-derived VP1 VLPs in Western blot with p
Western blot with anti-JCPyV VP1 (b), anti-HaPyV VP1 (c), anti-MCPyV VP1 (d
purified proteins were run on each gel. In lanes: 1 - HPyV16 L1 protein; 2 -
5 - WUPyV VP1 protein; 6 - MCPyV VP1 protein; 7 - HPyV6 VP1 protein; 8 - H
11 - HPyV10 VP1 protein; 12 - STLPyV VP1 protein; 13 - HPyV12 VP1 protein
Scientific Baltics); 16 - HaPyV VP1 protein11, 12). Interestingly, VP1 proteins derived from
HPyV13 and TSPyV were recognized by all four tested
polyclonal antibodies despite low similarity of both pro-
teins to WUPyV VP1 (30 and 29 % identity, respectively)
(Fig. 5, lines 9 and 14). In contrast, STLPyV VP1 protein
was hardly detected by only one antiserum raised against
MCPyV VP1 protein (43 % identity) (Fig. 5, line 12).
Anti-MCPyV VP1 polyclonal antibody additionally
cross-reacted with TSPyV (57 % identity) and HPyV10
(42 % identity) VP1 proteins (Fig. 5d, lines 9 and 11).
Anti-WUPyV VP1 polyclonal antibody showed a very
strong cross-reactivity with KIPyV VP1 (66 % identity)
but also detected HPyV7, HPyV10, and HPyV13 VP1
proteins identical to WUPyV VP1 only by 41, 33, and
48 %, accordingly (Fig. 5e, lines 4, 8, 11, and 14). Thus,
the cross-reactivity allowed detection of all purified
HPyV VP1 proteins by Western blot using only four
polyclonal antibodies.olyclonal antibodies. a, Coomassie blue-stained SDS-PAGE; (b, c, d, e),
), and anti-WUPyV VP1 (e) polyclonal antibodies. The same samples of
BKPyV VP1 protein; 3 - JCPyV VP1 protein; 4 - KIPyV VP1 protein;
PyV7 VP1 protein; 9 - TSPyV VP1 protein; 10 - HPyV9 VP1 protein;
; 14 - NJPyV VP1 protein; 15. Protein weight marker (Thermo Fisher
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KIPyV, WUPyV, HPyV6, HPyV7, TSPyV, HPyV9, HPyV10,
STLPyV, HPyV12, and NJPyV
All 11 purified VLPs were subjected to HA testing using
guinea pig erythrocytes. JCPyV-, BKPyV-, and SV40-
derived VP1 VLPs were used as controls. As shown in
Fig. 5, the HA titer of purified preparations of JCPyV- and
BKPyV-derived VP1 VLPs with known HA activity [37]
was down to a concentration of 0.78 μg mL−1. JCPyV- and
BKPyV-derived VP1 VLPs served as positive controls. The
preparation of SV40-derived VP1 VLPs did not show any
HA activity using guinea pig erythrocytes and so served as
a negative control [37]. HA activity was also confirmed for
MCPyV-derived VP1 VLPs with the HA titer down to a
concentration of 1.56 μg mL−1 [38]. KIPyV-, HPyV10-,
and HPyV12-derived VP1 VLPs demonstrated strong HA
activity, down to a concentration of 0.2 μg mL−1. TSPyV-
and HPyV9-derived VP1 VLPs showed HA activity down
to a concentration of 0.39 μg mL−1 and 0.78 μg mL−1, re-
spectively. WUPyV-, HPyV6-, HPyV7-, STLPyV-, and
NJPyV-derived VP1 VLPs did not show any HA activity
(Fig. 6).
Discussion
Recently, 11 new HPyVs have been identified. In contrast
to the better-studied PyVs, JCPyV, BKPyV, and to aFig. 6 HA activity of HPyV-derived VP1 VLPs. A 2-fold dilution series
of purified KIPyV-, WUPyV-, MCPyV-, HPyV6-, HPyV7-, TSPyV-, HPyV9-,
HPyV10-, STLPyV-, HPyV12-, and NJPyV-derived VP1 VLPs expressed
in S. cerevisiae were subjected to a HA assay with 1 % guinea pig
erythrocytes. Purified JCPyV- and BKPyV-derived VP1 VLPs were used
as positive controls, and SV40-derived VP1 VLPs were used as
negative controls. The concentrations of VP1-derived VLPs in μg
mL−1 are shown on the top. The bar indicates the highest VLP
concentration at which HA of guinea pig erythrocytes was observed
(HA titer)degree, MCPyV, the routes of infection, entry pathways,
and cell tropism of these new HPyVs remain unknown.
The variety and number of HPyVs indicate that they are
capable of self-propagating at low enough levels that do
not cause disease, except in immunosuppressed individ-
uals. To advance research on new HPyVs, development
of cell culture systems will be important. However, in
some applications, VLPs may be used instead, particu-
larly in cases where the wild-type virus is not easily
cultivated using cell cultures.
Recombinant VP1 proteins from previously discovered
PyVs were successfully produced in Escherichia coli,
yeast or baculovirus/insect cell expression systems [31].
Yeast or baculovirus/insect cell expression systems were
used for efficient production of self-assembled VP1 VLPs
derived from BKPyV, JCPyV, HaPyV and other PyVs
[29–31]. However, the recombinant VP1 proteins pro-
duced in E. coli were found mainly as pentamers which
self-assembled into VLPs during purification [28, 39].
Only JCPyV- and HaPyV-derived VP1 were shown to
form VLPs inside bacteria [40, 41]. Recently large-scale
and high-yield production yielding gram-per-liter levels
of MPyV VP1 fused with glutathione S-transferase
(GST) in E. coli was reported [42, 43]. VP1 protein was
purified as pentamer and VLPs were reassembled
in vitro after removal of the GST-tag. It should be noted
that the assembly of purified pentamers into VLPs al-
ways has a negative impact on the final yield [31],
though for MPyV VP1 the VLP reassembly yield was im-
proved and reached 42–56 % [44]. Nevertheless, other
authors have shown that yeast-produced MPyV derived
VP1 VLPs were more stable as compared to VLPs as-
sembled from pentamers purified from E. coli [45]. Simi-
larly, recombinant GST or 6His-tagged VP1 proteins or
VP1 pentamers but not VLPs derived from novel HPyVs
were produced in bacterial expression systems [15, 46,
47]. To synthesize HPyV-derived VP1 VLPs, mammalian
and/or insect cells have been used. MCPyV-derived VP1
VLPs have been generated in mammalian and insect
cells [48–50]. HPyV6-, HPyV7-, TSPyV-, HPyV9-, and
MWPyV/HPyV10-derived VP1 VLPs have also been suc-
cessfully produced in insect cells [33, 34, 51]. However,
VP1-derived VLPs from STLPyV, HPyV12, and NJPyV
have not been generated at all until now.
In this study, we demonstrated that VP1-derived VLPs
from 11 recently discovered HPyVs can be efficiently
produced in the yeast, S. cerevisiae. The synthesis of
VLPs using the yeast expression system has several ad-
vantages. S. cerevisiae is a GRAS (generally recognized
as safe) microorganism, free of toxins hazardous to hu-
man health [52, 53]. The preparation of products pro-
duced in yeast for human use is well established.
Additionally, recombinant VP1-derived VLP expression in
yeast is relatively cheaper than in insect or mammalian
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rently, S. cerevisiae is used in the production of vaccines
against the recombinant hepatitis B virus (Engerix, Glaxo
SmithKline; Gen H-B-Vax, Aventis Pasteur MSD GmbH)
and the human papillomavirus (Gardasil®) [54].
In this study, to generate 11 new HPyV-derived VP1
proteins in yeast, both native VP1-encoding genes and
genes optimized for expression in S. cerevisiae were
used. The lowest yield (approximately 0.4 mg per 1 g of
wet yeast biomass) of purified HPyV10- and HPyV12-
derived VP1 protein was obtained using the native gene
sequence and NJPyV-derived VP1 protein using gene
optimized for expression in S. cerevisiae (Table 1).
MCPyV-derived VP1 was also expressed using the native
gene sequence, but we obtained a high yield of this pro-
tein (approximately 0.8 mg per 1 g of wet yeast biomass,
Table 1), demonstrating that gene sequence is not the
only factor influencing the yield of recombinant protein.
The properties of recombinant proteins, stability, resist-
ance to proteases, and solubility, in particular, may have
also had an impact on purification efficiency and the
final yield. Therefore, the optimization of genes for use
in S. cerevisiae resulted in only slightly better yields of
VP1 from KIPyV, WUPyV, HPyV6, HPyV7, and STLPyV
(approximately 0.5–0.6 mg per 1 g of wet yeast biomass)
compared to HPyV10-derived VP1. The yield of highly-
soluble TSPyV-, HPyV9-, and HPyV12-derived VP1
VLPs, produced using optimized genes, was almost two
times greater (approximately 1 mg per 1 g of wet yeast
biomass). On the other hand, the difference between the
optimized versus native genes was obvious when a
shorter HPyV12 VP1 gene version was used. In this case,
utilization of optimized VP1 gene improved the yield of
VP1s364 by a factor of nearly 2.5.
The yeast system supported self-assembly of VP1-
derived VLPs from all 11 recently discovered HPyVs.
However, HPyV6- and WUPyV-derived VP1 VLP prep-
arations contained mainly smaller-sized capsids. In the
case of HPyV6-derived VP1 VLPs (Fig. 2d), small parti-
cles were also observed in other hosts. Electron micro-
graphs of HPyV6- and HPyV7-derived VP1 VLPs
purified from mammalian 293TT cells show particles
smaller than 45–50 nm in diameter [10]. The propor-
tion of small HPyV6-derived VP1 VLPs produced in in-
sect cells was similar to that purified in yeast. Purified
HPyV7-derived VP1 VLPs produced both in insect and
yeast cells self-assemble into typical PyV-derived VLPs
[33]. In contrast, small particles predominate in prepa-
rations of HPyV9-dervied VP1 VLPs purified from
insect cells [33]. However, in our study, the yeast-
generated HPyV9-derived VP1 VLPs assembled into
mostly typical PyV-like particles with diameters of ap-
proximately 45 nm (Fig. 2g). An explanation for differ-
ent efficiencies in forming normally-sized VLPs fromdifferent PyVs remains elusive. It has been proposed
that variation in particle size in SV40 actually indicates
the presence of mosaic VLPs, which form from a
combination of different geometries of pentamer inter-
actions [55]. Due to numerous possible interactions,
SV40 pentamers can self-assemble into a broad array of
shapes; this assembly can be redirected by different nu-
cleic acids serving as a scaffold and as a nucleating fac-
tor [55]. Similarly, MPyV-derived VP1 self-assembles
into VLPs that are 26, 32, and 50 nm in diameter [56].
It has been suggested that the N-terminal arm of VP1
forms a clamp to hold the C-terminal protrusions from
neighboring capsomeres in place [57], connecting the
N-terminal arms of VP1 from different capsomeres via
the intercapsomeric disulphide bridges [45]. Flexibility
in this clamping mechanism allows capsomeres to exist
in both the pentavalent and hexavalent state [28, 58]
and permits the assembly of polymorphic particles in
PyVs [56, 59]. On the other hand, sometimes even a
single change in an aa residue can influence the size of
VP1-derived VLPs. This has been shown in the HaPyV,
wherein a single A336G aa exchange in the C-terminal
arm of VP1 results in smaller VP1-derived VLPs that
are 20 nm in diameter [60]. The HPyV6 and HPyV7 ge-
nomes that have been sequenced so far reveal
naturally-occurring VP1 aa sequence variation [10]; it is
not known how such variation influences VLP assem-
bly. Because smaller particles predominate among
HPyV6-derived VP1 VLPs produced in yeast, insect,
and mammalian cells, it is possible that some aa vari-
ants can support self-assembly of normal-sized HPyV6-
derived VP1 VLPs.
As a result of our attempts to express HPyV12-derived
VP1 VLPs in yeast and alignment of various PyV-derived
VP1 N-terminal sequences, our data suggest that the
true translation initiation site predicted by the VP1-
encoding ORF is the second translation initiation site
[15]. Removal of the 16-aa-long N-terminal peptide
greatly improved VP1 expression and VLP formation.
There are only a few such cases known in other PyV ge-
nomes. HaPyV-, JCPyV-, and SV40-derived VP1 is syn-
thesized starting from the second of two potential
translation initiation sites in their respective genes
(Fig. 4) [61]. The development of cell culture systems for
the production of HPyV12 and determination of the N-
terminal sequence of VP1 isolated from the virus capsid
could be useful in confirming the true translation initi-
ation start site.
HA activity using guinea pig erythrocytes can expand
the number of potential applications for VP1-derived
VLPs. They can be used as antigens, not only in enzyme
immunoassays, but also in more specific HA inhibition
assays to detect corresponding HPyV-specific anti-
bodies in human sera [62]. On the other hand, the HA
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as an initial index of virus cell-binding properties,
which are related to viral spreading, cell tropism, and
pathogenicity [63, 64].
The HA activity of JCPyV is associated with the bind-
ing of VP1 to sialic acid residues [63–65]. In contrast,
SV40 has no HA activity and uses other receptor mole-
cules, e.g., major histocompatibility complex class I
molecules [66]. It has been reported that SV40 might
bind to sialic acid residues present on ganglioside GM1,
but the steric arrangement of the binding amino acids
differs from that of hemagglutinating viruses, such as
MPyV [67–69]. Consistent with these observations, it
has been shown that mutations in the sialic acid bind-
ing site impair HA of MCPyV-derived VP1 capsids [70].
The variation in HA activity observed in this study
among VP1-derived VLPs from different PyVs might re-
flect diversity in receptor recognition among PyVs. HA
of guinea pig erythrocytes by KIPyV-, TSPyV-, HPyV9-,
HPyV10-, and HPyV12-derived VP1 VLPs suggests that
these viruses might use sialic acid residues to bind the
virus particle to the host cell. In contrast, WUPyV-,
HPyV6-, HPyV7-, STLPyV-, and NJPyV-derived VP1
VLPs showed no HA activity and thus more likely use
other receptor molecules. Indeed, according to the
solved high-resolution crystal structure of HPyV9 VP1
in complex with the three putative oligosaccharide re-
ceptors identified by glycan microarray screening,
HPyV9 engages short sialylated oligosaccharides [71].
Consistent with these observations, HPyV9-derived
VP1 VLPs showed HA of guinea pig erythrocytes in our
study. Protein structure analysis of HPyV6- and
HPyV7-derived VP1 reveals an obstructed sialic acid
binding site [72]. Additionally, VP1 derived from
HPyV6 and HPyV7 does not interact with sialylated
compounds in solution or in cultured human cells [72].
Stroh et al. suggest that it is still possible that HPyV6
and HPyV7 bind sialic acids at a site in the fully assem-
bled virus, but not in the free VP1 pentamer [72]. In
our study, the yeast-produced HPyV6- and HPyV7-
derived VP1 VLPs had no HA activity, supporting the
recent observations that these two viruses bind non-
sialylated receptors. The VP1-derived VLPs from two
other members of the genus Wukipolyomavirus (KIPyV
and WUPyV) differed in their ability to hemagglutinate
guinea pig erythrocytes, despite the fact that none of
the sialic acid binding residues found in SV40, JCPyV,
or MPyV are conserved in the WUPyV and KIPyV VP1
structures [73]. KIPyV-derived VP1 VLPs efficiently
hemagglutinated guinea pig erythrocytes, whereas
WUPyV-derived VP1 VLPs did not show any HA activ-
ity. The data suggest that these two similar viruses
might use different receptor molecules to bind host
cells.Conclusions
The yeast expression system was successfully adapted
for high-throughput production of recombinant VP1-
derived VLPs from 11 newly identified HPyVs. Although
HPyV12 VP1 was predicted to encode a 380-aa-long
protein, our findings suggest that translation starts not
at the first, but rather at the second, of two potential ini-
tiation sites in the VP1-encoding ORF, resulting in a
364-aa-long protein. Yeast-generated recombinant VP1-
derived VLPs from different HPyVs demonstrated distinct
HA activities and may be useful in virus diagnostics, cap-
sid structure studies, or the investigation of entry path-
ways and cell tropism of new HPyVs until cell culture
systems for new HPyVs are developed.
Methods
Generation of yeast expression plasmids harboring VP1
genes
Construction of plasmids and other genetic manipula-
tions were performed according to standard procedures
[74] using enzymes and kits purchased from UAB
Thermo Fisher Scientific Baltics (Vilnius, Lithuania).
Genes encoding VP1 from KIPyV, WUPyV, HPyV6,
HPyV7, TSPyV, HPyV9, STLPyV, and NJPyV were
codon-optimized for expression in yeast [GenBank
KP293742, KP293743, KP293744, KP293745, KP293746,
KP293747, and KP293749] and commercially synthe-
sized by GenScript (Piscataway, NJ, USA). The MCPyV
VP1-encoding sequence was amplified using Phusion
High-Fidelity DNA Polymerase (Thermo Fisher Scien-
tific Baltics) from a healthy volunteer skin swab and then
sequenced [GenBank: KP293741]. The samples of hu-
man skin swabs were collected and used with the ap-
proval of Vilnius Regional Research Ethics Committee
(Permit no. 158200-7-070-17) within the project “Devel-
opment of diagnostic tools for Merkel cell polyomavirus”
during 2009–2010. HPyV10 VP1 was synthesized ac-
cording to the native virus gene sequence without codon
optimization, but with two nucleotide changes to re-
move restriction endonuclease XbaI recognition sites
[GenBank: KP293748].
Two versions of the HPyV12 VP1 protein, consisting
of a 380-aa chain, were commercially synthesized by
GenScript: 1) HPyV12 VP1n380 [GenBank: KP293750],
according to the native virus gene sequence with one
nucleotide changed to remove a restriction endonuclease
XbaI recognition site, and 2) HPyV12 VP1s380 with a S.
cerevisiae codon-optimized gene sequence [GenBank:
KP293751]. Shorter 364-aa-long versions of the HPyV12
VP1 protein with native (HPyV12 VP1n364) and codon-
optimized sequences (HPyV12 VP1s364) were amplified
from HPyV12 VP1n380 and HPyV12 VP1s380 using Phu-
sion High-Fidelity DNA Polymerase and the primers:
HPy12-VP1ATG2-NX:




All VP1-encoding DNA fragments were sub-cloned
into the XbaI site of the yeast expression vector pFX7
for target protein expression [29]. Recombinants were
screened in Escherichia coli DH5α cells.
Yeast cultivation conditions and analysis of VP1
expression
The vector pFX7, without any insert or constructed
plasmids, pFX7-KIPyV-VP1, pFX7-WUPyV-VP1, pFX7-




VP1s364, and pFX7-NJPyV-VP1 were transformed into
the S. cerevisiae strain, AH22-214 (a, leu2-3,112, his4-
519). The growing conditions for yeast transformants
harboring plasmids with VP1-encoding genes from dif-
ferent HPyVs and conditions for induction of VP1 syn-
thesis were similar to that previously described [75].
Briefly, yeast cells were first cultured in glucose- then
galactose-containing induction media for 24 and 18 h,
respectively. Yeast cells harboring recombinant proteins
were collected by centrifugation, washed with distillate
water, and then stored at −20 °C until purification or
analysis by electrophoresis in 12 % SDS-PAGE. For ana-
lysis of VP1 expression, harvested yeast cells (20–
50 mg) were suspended in 20–50 μL of DB150 buffer
(150 mM NaCl, 1 mM CaCl2, 0.25 M L-Arginine,
0.001 % Triton X-100, 10 mM Tris/HCl, pH 7.2), lysed
by vortexing with an equal volume of glass beads for
7 min, and then cooled on ice for 1 min between each
vortexing step. A 15–30-μL aliquot of each yeast lysate
and the supernatant obtained after centrifugation of
each yeast lysate were prepared for analysis by mixing
with the SDS-PAGE sample buffer (Thermo Fisher Sci-
entific Baltics) and then boiling for 5 min. Prepared
samples were then subjected to SDS-PAGE and run in
SDS-Tris-glycine buffer. The resultant gel was stained
with Coomassie brilliant blue (Sigma-Aldrich, St. Louis,
MO, USA) for protein band visualization.
Purification and characterization of HPyV VP1-derived
VLPs
Recombinant VP1 protein purification was carried out
as previously described [75]. Briefly, yeast cells contain-
ing recombinant VP1 protein were suspended in DB450
buffer (450 mM NaCl, 1 mM CaCl2, 0.001 % 0.25 M L-
Arginine, and Trition X-100, in 10 mM Tris/HCl-buffer,
pH 7.2) with 2 mM PMSF and EDTA-free Complete
Protease Inhibitor Cocktail tablets (Roche Diagnostics,Mannheim, Germany), and then were homogenized with
glass beads using Bead-Beater GB26 (BioSpec Products,
Inc., Bartlesville, USA). The supernatant collected after
centrifugation of yeast lysate was loaded onto a 20–69 %
sucrose gradient in DB150 buffer and then centrifuged
at 100,000 × g (Beckman Optima LE-80 K Ultracentri-
fuge, Brea, CA, USA) overnight at 4 °C. Thereafter, 2-
mL fractions were collected and samples from each frac-
tion were analyzed using Coomassie brilliant blue-
stained SDS-PAGE. Fractions containing VP1 were
pooled, diluted in DB150 buffer, and after a 0.5 h incu-
bation step with DNAse-free RNAse (Thermo Fisher
Scientific Baltics), VP1-derived VLPs were concentrated
by ultracentrifugation at 100,000 × g for 4 h at 4 °C.
Afterwards, pellets containing VP1 were dissolved in
DB150 buffer and subjected to ultracentrifugation on a
CsCl gradient with densities ranging from 1.23 to
1.46 g mL−1 at 100,000 × g overnight at 4 °C. Fractions
were collected and analyzed, as described above. After
pooling and diluting purified VP1-containing fractions
in DB150 buffer, VP1-derived VLPs were precipitated by
ultracentrifugation for 4 h at 100,000 × g. Pellets with
VP1-derived VLPs were dissolved in PBS, dialyzed
against PBS overnight, aliquoted, and then lyophilized or
stored in PBS in 50 % glycerol at −20 °C. JCPyV, BKPyV,
SV40, and HaPyV VP1-derived VLPs were prepared as
previously described [30].
To confirm VLP assembly of recombinant VP1 pro-
teins generated in yeast, a sample of VP1 purified by
ultracentrifugation was placed on 300-mesh carbon-
coated palladium grid. VP1-derived VLPs adhering to
the grid were negatively stained with 2 % aqueous uranyl
acetate solution and examined with a Morgagni 268
electron microscope (FEI Inc., Hillsboro, OR, USA).
Western blot
Samples of purified recombinant VP1 proteins derived
from all HPyVs and HaPyV were mixed with the SDS-
PAGE sample buffer (Thermo Fisher Scientific Baltics),
boiled for 5 min, applied to a SDS-PAGE and run in
SDS-Tris-glycine buffer. Protein bands in SDS-PAGE
were electro-transferred to Immobilon P membrane
(Millipore, Bedford, MA, USA) or visualized by staining
with Coomassie brilliant blue (Sigma-Aldrich, St. Louis,
MO, USA). The membranes were blocked with 5 % milk
in TTBS (0.1 % Tween 20, 0.1 M Tris, 0.3 M NaCl,
pH 7.4) and incubated overnight in the relevant antibody
solutions at room temperature. Anti-JCPyV, −MCPyV,
and -WUPyV VP1 mouse sera (raised against the re-
spective VP1 protein) and anti-HaPyV VP1 rabbit serum
[75] were diluted 1:500, 1:300, 1:300, and 1:1000, re-
spectively, in TTBS. After incubation with the diluted
antibodies, the membranes were incubated for 2 h with
horseradish peroxidase-labeled anti-mouse or anti-rabbit
Norkiene et al. BMC Biotechnology  (2015) 15:68 Page 12 of 14IgG conjugate (Bio-Rad, Hercules, CA, USA) diluted
1:1000. The peroxidase-mediated protein band staining
was performed by adding 4-chloro-1-naphtol (BioChem-
ica, Darmstadt, Germany) and H2O2 (Roth, Karlsruhe,
Germany).
Hemagglutination assay
VLPs were subjected to a HA assay using guinea pig
erythrocytes in a U-shaped microtiter plate. VLPs of each
purified VP1 protein were serially diluted (50 μg mL−1 to
0.025 μg mL−1) in 25 μL PBS and mixed with 25 μL of a
1 % (v/v) guinea pig erythrocyte suspension in PBS. HA
activity was recorded after a 3 h incubation at 4 °C. The
HA titer was defined as the reciprocal of the highest
antigen dilution clearly showing HA.
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